1. Show article details.

    Peregrine Pharmaceuticals Reports Fourth Quarter and Year-End Fiscal Year 2015 Financial Results and Recent Developments

    GlobeNewswire – 4:05 PM ET 07/14/2015

    -- Phase III SUNRISE Clinical Trial on Track to Complete Patient Enrollment by Calendar Year-End 2015 – -- Initiation of Later-Stage Bavituximab Trials to Expand Commercial Potential in NSCLC and Breast Cancer Planned for Second Half of Calendar Year 2015 -- -- Avid’s Contract Manufacturing Revenue Exceeds $26 Million for Fiscal Year 2015 – TUSTIN, Calif., July 14, 2015 -- Peregrine Pharm...

  2. Show article details.

    Peregrine to Report Fourth Quarter and Year-End Fiscal Year 2015 Financial Results After Market Close on July 14, 2015

    GlobeNewswire – 4:05 PM ET 07/07/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing novel investigational products that help harness the body's own immune system to fight cancer, today announced that it will report financial results for the fourth quarter and fiscal year 2015 ended April 30, 2015 on July 14, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Dayligh...

  3. Show article details.

    Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab

    GlobeNewswire – 8:30 AM ET 06/25/2015

    -Bavituximab Patent Secured in Countries Across Europe- -Bavituximab Phase III Clinical Trial Underway at Over 150 Worldwide Clinical Sites Including Over 75 Sites in Eight European Countries- Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on developing novel investigational products that help harness the body’s own immune system to fight cancer, today announced that the...

  4. Show article details.

    Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

    GlobeNewswire – 8:30 AM ET 06/05/2015

    Peregrine Pharmaceuticals, Inc. (PPHM) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock. The quarterly dividend on the Series E Preferred Stock is payable on July 1, 2015 to holders of record at the close of business on June 19, 2015.

  5. Show article details.

    Data Presentations at ASCO Demonstrate the Ability of Peregrine Pharmaceuticals' Bavituximab to Activate Tumor Targeting Immune Cells in PD-L1 Negative NSCLC Tumors

    GlobeNewswire – 9:00 AM ET 06/01/2015

    - New Data Show that Bavituximab Alone and in Combination with Docetaxel Elicits a Tumor-Specific Immune Response in PD-L1 Negative Tumors Extracted from NSCLC Patients - - PS-Targeting Antibodies Combined with Anti-PD-1 Reverses Tumor Immunosuppression and Activates Tumor Fighting CD8+ Immune Cells in Models of Melanoma and Breast Cancer - - Encouraging Data in Patients with Advanced Liver Can...

  6. Show article details.

    Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program

    GlobeNewswire – 8:30 AM ET 06/01/2015

    - Phase II Trial to Evaluate Combination of Bavituximab and Opdivo® in Non-Small Cell Lung Cancer - - Phase II/III Combination Trial to Advance Bavituximab with Chemotherapy Combinations in HER2 Negative Breast Cancer - - New Studies Expected to be Underway as Phase III SUNRISE Trial in Lung Cancer Completes Enrollment by Calendar Year-End - TUSTIN, Calif., June 1, 2015 -- Peregrine Pharmaceuti...

  7. Show article details.

    Peregrine Pharmaceuticals Enters Into Research Collaboration to Investigate Novel PS-Targeting Immunotherapy Combinations

    GlobeNewswire – 8:30 AM ET 05/29/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development for the treatment of lung cancer, today announced that the company has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to explore the potential of Peregrine's proprietary phosphatidylserine-targeting antibod...

  8. Show article details.

    Peregrine Pharmaceuticals Announces Webcast of Immunotherapy Roundtable at ASCO Annual Meeting

    GlobeNewswire – 4:00 PM ET 05/27/2015

    Peregrine Pharmaceuticals (PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development for the treatment of lung cancer, invites investors and the general public to listen to a webcast of its roundtable discussion in conjunction with the 2015 American Society of Clinical Oncology Annual Meeting.

  9. Show article details.

    Peregrine Pharmaceuticals' Immuno-Oncology Agent Bavituximab to be Highlighted in Three Presentations at 2015 ASCO Annual Meeting

    GlobeNewswire – 5:00 PM ET 05/13/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, today announced the presentation of three posters at the 2015 American Society of Clinical Oncology Annual Meeting, to be held May 29-June 2, 2015 in Chicago, Illinois.

  10. Show article details.

    Preclinical Data Presented at AACR Demonstrate Synergistic Anti-Tumor Effects of Peregrine Pharmaceuticals' Phosphatidylserine (PS)-Targeting Antibodies With Immune Checkpoint Inhibitors in Models of Melanoma and Breast Cancer

    GlobeNewswire – 8:00 AM ET 04/21/2015

    - Combination Treatment Reduces Tumor Immune System Blockade and Enhances Tumor Specific Immune Responses - - Studies Reveal Significant Increases in Tumor-Infiltrating CD8+ T Cells and Immune-Activating Cytokines while Decreasing Tumor-Promoting Macrophages and Myeloid Cells - TUSTIN, Calif., April 21, 2015 -- Peregrine Pharmaceuticals, Inc. (PPHM) today announced the presentation of data from precl...

  11. Show article details.

    Data Presented at AACR Demonstrate Peregrine Pharmaceuticals' Bavituximab Induces Immune Activation in PD-L1 Negative NSCLC Tumors

    GlobeNewswire – 8:00 AM ET 04/20/2015

    - Bavituximab Alone and in Combination with Docetaxel Elicit a Tumor-Specific Immune Response in PD-L1 Negative Tumors Extracted from NSCLC Patients - - Immune Modulating Results Consistent with Previously Conducted Translational Studies in Liver Cancer - - Presented Data Further Support Clinical Studies Evaluating the Effectiveness of Bavituximab Immunotherapy Combinations in Patients with PD-...

  12. Show article details.

    Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting

    GlobeNewswire – 8:00 AM ET 04/14/2015

    Peregrine Pharmaceuticals (PPHM) today announced that two preclinical abstracts and one clinical translation abstract are scheduled for poster presentations at the 106th Annual Meeting of the American Association for Cancer Research, to be held April 18-22, 2015 in Philadelphia, Pennsylvania. Abstract details: Abstract Number: 274.

  13. Show article details.

    Peregrine Pharmaceuticals Announces Promising Bavituximab Phase I Data Published in the Peer-Reviewed Journal Cancer Medicine in Advanced Metastatic Breast Cancer

    GlobeNewswire – 12:45 PM ET 03/31/2015

    - Combination of Bavituximab and Paclitaxel Achieved an 85% Objective Response- - Design of Phase II Clinical Trial Underway - Peregrine Pharmaceuticals (PPHM), today announced the peer-reviewed publication of clinical data from a Phase I investigator-sponsored trial evaluating the company's lead investigational immunotherapy bavituximab plus paclitaxel therapy in patients with HER2-negative metastat...

  14. Show article details.

    Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2015 Financial Results and Recent Developments

    GlobeNewswire – 4:00 PM ET 03/12/2015

    - SUNRISE Phase III Lung Cancer Trial On Track to Complete Enrollment by Calendar Year-End - - Encouraging and Consistent Data from Immuno-Oncology Development Program Continue to Support Bavituximab's Immunostimulatory Mechanism - - Avid Bioservices Increases Revenue Guidance to Between $23 and $25 Million for Full Fiscal Year 2015 Based on Strong Demand for Services – TUSTIN, Calif., March...

  15. Show article details.

    Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock

    GlobeNewswire – 4:00 PM ET 03/10/2015

    Peregrine Pharmaceuticals, Inc. (PPHM) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock. The quarterly dividend on the Series E Preferred Stock is payable on April 1, 2015 to holders of record at the close of business on March 20, 2015.

  16. Show article details.

    Peregrine Pharmaceuticals to Report Third Quarter Fiscal 2015 Financial Results After Market on March 12, 2015

    GlobeNewswire – 4:00 PM ET 03/05/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, today announced that it will report financial results for the third quarter fiscal year 2015 ended January 31, 2015 on March 12, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Daylight Time.

  17. Show article details.

    Peregrine Pharmaceuticals to Present at the 27th Annual ROTH Conference

    GlobeNewswire – 4:00 PM ET 03/02/2015

    Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology antibody targeting the highly immunosuppressive phosphatidylserine signaling pathway, towards commercialization and providing integrated cGMP clinical and commercial bio-manufacturing services, announced that Steven W. King, president and chief executive officer, will present a...

  18. Show article details.

    Newly Presented Data Shows That Peregrine Pharmaceuticals' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity of Immune Checkpoint Inhibitors PD-1 and CTLA-4 in Models of Breast Cancer and Melanoma

    Market Wire – 8:30 AM ET 02/09/2015

    02/09/15 -- Peregrine Pharmaceuticals, Inc. (PPHM) today announced preclinical data presentations showing that the PS-targeting antibody equivalent to bavituximab combined with an anti-PD-1 antibody displayed statistically significant improvement in tumor fighting immune cells, activation signals and cytokines in a model of melanoma compared to anti-PD-1 alone.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.